Onzima Ventures Share Discussion Threads

[fido] 20/7/2016 08:45

Not only does this look like a scam but it also looks like a well organised one at that. For wahlberg talking about pie in the sky returns knowing full well that a number of financials have serious concerns about the whole set up of onz and other companies where investors were fleeced out of every penny is deplorable.

[bigego] 20/7/2016 08:39

Whilst you are at it you dirty little creature a bit of background on why you are obsessed with this share and your previous connections to UTN would add some balance.

Failed business consultant, failed investor, failed de-ramper.

Is there anything you are good at?

[wahlberg] 20/7/2016 08:32

The viagra drug deal will be the one that really sparks up the share price.

£4/5m upfront royalty?

£30-60m in annual royalties

Low overheads, 80% margin

Patent strategy to protect long-term revenue generation

It's one of the best potential stocks on the market.

ONZ

[wahlberg] 20/7/2016 08:28

And in reality, n4 should be closer to a £25m valuation already given their sector peers at similar stages.

Once the annual royalties start rolling in then a simple EBIT multiple will suggest a valuation in excess of £100m

[bigego] 20/7/2016 08:27

You are a sad washed up nobody.

Give it a break before you get yourself into very deep trouble.

[wahlberg] 20/7/2016 08:26

Great summary.

We know how quickly Nigel will take n4 to a £25-50m size company given by replicating his previous success.

Just waiting for the break of 1.75 and then we're off.

Nigel must be feeling good with his 30m or so shares in ONZ

Very relaxed sitting back and watching this one rise over the coming months.

[fido] 20/7/2016 08:13

keya500,
That is unbelievable pie in the sky rubbish.
In a short while I will post information why investors should not touch onz with a barge pole for fear of losing every penny.
That write up is so rose tinted its unbelievable.

[fido] 20/7/2016 08:13

keya500,
That is unbelievable pie in the sky rubbish.
In a short while I will post information why investors should not touch onz with a barge pole for fear of losing every penny.
That write up is so rose tinted its unbelievable.

[keya5000] 20/7/2016 07:42

Great post from lse.

GraphiteTech 5,112 posts
Reasons to buy.
From a respected source. Bits removed to protect the senders identity. Comments below are reasons to buy ONZ.

I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!):

-Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term)
-Results on sildenafil PoC studies
-Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago
-Securing a major partner for the Cocrys platform as a whole
-Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development
-Results on further testing of Nuvac/Nuvec platforms
-Securing a major partner to fund the further development of these platforms
-Announcement of next major product to be developed on the platforms after sildenafil

Beyond these specific catalysts, what I really like about the N4 story is:

-Nigel’s track record in the space
-Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market)
-The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £)
-The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price
-The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!))

I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future.

The rationale for this is based on:
- our CEO hinting at increasing exposure to the space (in the Year End results);
- the creation of the two divis

[keya5000] 20/7/2016 07:41

GraphiteTech 5,112 posts
Reasons to buy.
From a respected source. Bits removed to protect the senders identity. Comments below are reasons to buy ONZ.

I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!):

-Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term)
-Results on sildenafil PoC studies
-Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago
-Securing a major partner for the Cocrys platform as a whole
-Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development
-Results on further testing of Nuvac/Nuvec platforms
-Securing a major partner to fund the further development of these platforms
-Announcement of next major product to be developed on the platforms after sildenafil

Beyond these specific catalysts, what I really like about the N4 story is:

-Nigel’s track record in the space
-Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market)
-The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £)
-The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price
-The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!))

I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future.

The rationale for this is based on:
- our CEO hinting at increasing exposure to the space (in the Year End results);
- the creation of the two divis

[keya5000] 20/7/2016 07:40

From lse.

GraphiteTech 5,112 posts
Reasons to buy.
From a respected source. Bits removed to protect the senders identity. Comments below are reasons to buy ONZ.

I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!):

-Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term)
-Results on sildenafil PoC studies
-Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago
-Securing a major partner for the Cocrys platform as a whole
-Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development
-Results on further testing of Nuvac/Nuvec platforms
-Securing a major partner to fund the further development of these platforms
-Announcement of next major product to be developed on the platforms after sildenafil

Beyond these specific catalysts, what I really like about the N4 story is:

-Nigel’s track record in the space
-Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market)
-The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £)
-The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price
-The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’; its market leading Viagra brand (“Viagra XL”?!))

I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future.

The rationale for this is based on:
- our CEO hinting at increasing exposure to the space (in the Year End results);
- the creation of the two divis

[fido] 19/7/2016 23:08

RAMPER.
AND YOU ARE STILL A SECOND RATE RAMPER.
You are aware that there are a number of financial bodies that have serious concerns about what is going on, not just with ONZ but with a number of companies,and yet you did not tell people that as you were saying this was going from a £2.5m cap to a £500m cap
What you don`t have a grip on is that there is a good chance people could lose every penny of their investment here or maybe you do and like some of the things I`ve been reading, your only here and other places to RAMP the stock so that others lose out.
Time will tell but people are starting to cotton onto what`s happening because its being repeated over and over again.

[wahlberg] 19/7/2016 18:35

Foil hat, haha

Fido joins the likes of BMD and TW, a complete tool.

Dedicating his days to checking twitter, advfn and lse for Onz posts, watching videos again and again,

And still can't spell imminent.


Hahahahahaha

[keya5000] 19/7/2016 18:03

That's a very strong statement.

I do hope you have the back up for when the legal orders start landing on your door step.

[fido] 19/7/2016 16:14

bigego,
I am investigating what I consider to be an investor scam that has been played out in a number of companies with the same people involved. What I am currently looking at is the part BB`s and in particular the blatant ramping of a stock by certain posters plays in this.
My research thus far would indicate my fears are justified and that it is likely that shareholders stand a good chance of being fleeced.
The question is, is that fleecing deliberately orchestrated and whether those involved can be made accountable.
I am already in contact with the LSE and a couple of journalists who share my concerns.

[bigego] 19/7/2016 10:11

PMSL, you are one complete nut job.

[fido] 19/7/2016 09:45

keya5000,
At the present time I am investigating what could be considered untoward dealings which could possibly see investors losing most if not all of their investment. If you wish to challenge that then I would suggest that you do some research but for the moment I have some grave concerns about the goings on here and peoples complexities in it.
I will of course get back to you on that.

[keya5000] 19/7/2016 07:23

Fido I asked had it gone down yesterday it hadn't despite the sells outweighing the buys.

[fido] 18/7/2016 23:53

PatientCapital
wHAT PART OF I AM A SHAREHOLDER ARE YOU NOT GETTING.

[fido] 18/7/2016 23:41

keya5000,
Don`t be so stupid.

Buy Volume 1,178,058

Sell Volume 1,992,922 Including a 1 million sell.

[fido] 18/7/2016 23:34

RAMPER, you ramp like someone without a clue.
Second thoughts, you don`t have a clue.

[wahlberg] 18/7/2016 18:22

He posts like a 5 yr old. An increasingly desperate and frustrated one.

Quite funny mind

[patientcapital] 18/7/2016 18:09

What seems strange is someone who 'claims' to be a shareholder being so negative about their investment. Most rational investors sell holdings when they no longer expect to receive positive returns from them.

[keya5000] 18/7/2016 17:47

Did it go down today?